321P - Clinical course comparison between patients with type 1 and type 2 uterine endometrial cancers

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Endometrial Cancer
Presenter Yae Takehara
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors Y. Takehara1, M. Yunokawa1, S. Sasada1, E. Noguchi1, A. Shimomura1, T. Shimoi1, K. Yonemori1, C. Shimizu1, T. Kato2, K. Tamura1
  • 1Breast And Medical Oncology / Rare Cancer Center, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2Gynecology, National Cancer Center Hospital, 104-0045 - Tokyo/JP



Uterine endometrial cancer is classified into two groups: type 1, which includes grades 1 and 2 endometrial carcinoma; and type 2, which includes grade 3 endometrial carcinoma, serous adenocarcinoma, clear cell carcinoma, and mucinous carcinoma. No studies assessing optimal surveillance after initial treatment for endometrial cancer have been performed. This study aimed to determine the association between cancer type and recurrence time as well as the effect of prognostic factors.


Charts for patients with endometrial cancer who underwent surgery between January 2005 and December 2011 were retrospectively reviewed, and clinicopathological features and clinical courses were compared between patients with type 1 and type 2 disease. Cumulative incidence curves for recurrence were estimated, and the association between the time of relapse and cancer type was assessed by multivariate logistic regression.


Three hundred seventeen patients with type 1 disease and 106 patients with type 2 disease were evaluable. Advanced stage (stage III or IV) was more commonly found among patients with type 2 endometrial cancer (12% vs. 30.2%, p 


Type 2 of endometrial cancer recurred earlier than type 1 disease. More careful surveillance after initial treatment is needed for patients with type 2 endometrial cancer, especially in the first 2 years.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.